TELK -- Telik, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TELK -- Telik, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (343)	1/16/2003 2:51:12 PM
From: tom pope	Read Replies (1) of 887

Briefing: Telik upped to Overweight at Lehman (12.94 +0.84) Lehman upgrades to OVERWEIGHT from Underweight and raises price target to $18 from $14. Rating change is based on stock's more reasonable valuation following the full vetting of risk associated with TLK-286 colorectal data and a more optimistic outlook ahead as the company initiates a phase III trial in ovarian cancer.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next